Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Study of Two Dose Schedules of PI-88 in Combination With Docetaxel in Patients With Androgen-independent Prostate Cancer

NCT00268593 is registered in ClinicalTrials.gov with Progen Pharmaceuticals as lead sponsor.

NCT NCT00268593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00268593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Study of Two Dose Schedules of PI-88 in Combination With Docetaxel in Patients With Androgen-independent Prostate Cancer
Lead sponsor
Progen Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
February 29, 2008
Enrollment
48 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer